CHMP recommends 16 new medicines at July meeting

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has released a list of products recommended for Marketing Authorisation during its July meeting.

Amongst these was Onpattro (patisiran), a polyneuropathy drug, which was approved via the EMA’s Accelerated Assessment procedure under which medicines with major public health impacts can be reviewed in five months rather than seven.

Onpattro and the cystic fibrosis drug Symkevi (tezacaftor or ivacaftor), which also gained a recommendation, are orphan medicines.

In total twelve products were recommended in July, with no rejections.

Further details can be found here.

Tagged with

Published 27. July 2018 in News, News EU, News France, News Germany, News Ireland, News Italy, News Spain, News UK